This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

More Biotech Lessons Learned From JPM 2012

Stocks in this article: INHX ACHN AMAG ONTY CLDX GERN CELG

Most provocative quote from the conference: Merck's (MRK) worldwide head of licensing and acquisitions Roger Pomerantz telling Bloomberg, "Our goal is to be a leader in hepatitis C, and we will do what it takes to get there."

Does that include making a hostile bid for Inhibitex (INHX)? Hmmm….

On a related note, Merck's research chief doesn't believe the race to develop an all-oral Hep C regimen is winner-take-all. Speaking during Merck's breakout session, Kim said, "It's not clear how many patients the healthcare system can take at one time. It's also not clear how much the payors are going to open up the doors at one time. So the notion that you have a whole bunch of patients just rushing in to get treated and then everything's done, we think, is not the right way to think about this. There is going to be time to sort of what is the optimal combination therapy."

Two drugs I heard about for the first time this week that I want to dig into further: Clovis Oncology's (CLVS) CO-101 (with its companion diagnostic) for pancreatic cancer and Nektar Therapeutics' (NKTR) NKTR181, a novel painkiller designed to cross the blood-brain barrier more slowly and therefore reduce euphoria that can lead to abuse.

Question: Do investors trust Ariad Pharmaceuticals' (ARIA) CEO Harvey Berger to commercialize the leukemia drug ponatinib on his own?

Celgene (CELG - Get Report): Rocking. Strong 2012 guidance, a management team exuded confidence and a calendar filled with big-time regulatory and clinical catalysts.

Déjà vu: Sam Waksal back in front of a podium at the J.P. Morgan conference, this time pitching his new private company Kadmon Pharmaceuticals (which, by the way, is also involved in the hepatitis C drug game.) The last time Waksal spoke publicly at this conference wasn't fun -- for him.

Burrito porn. If you must know, Taqueria Cancun at Mission and 19th St.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs